Enhanced adherence to HCV therapy with higher dose ribavirin formulation

Final analyses from the ADHERE registry

Imtiaz Alam, T. Stainbrook, B. Cecil, K. D. Kistler

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background Poor adherence to Hepatitis C virus (HCV) treatment is an important cause of treatment failure. Traditional ribavirin 200 mg (RBV) treatment is associated with a significant daily pill burden. RibaPak (RBP), available as 400 mg and 600 mg ribavirin tablets, offers simplified dosing at two pills daily. Aim To examine whether improved adherence was associated with RBP vs. RBV. Methods Accurate Dosing in Hepatitis C: Examining the RibaPak Experience (ADHERE) was a U.S., multi-centre, prospective registry capturing data on adherence with RBP vs. RBV in adults with HCV. Adherence was measured by the proportion of subjects remaining on treatment at weeks 4, 12 and 24; by pill counts; and by the proportion of subjects who took ≥80% of their prescribed dose. Results A total of 503 patients (RBP = 346, RBV = 157) from 33 sites were included. A greater proportion of RBV vs. RBP subjects prematurely discontinued treatment. At 12 and 24 weeks, a greater proportion of RBP vs. RBV subjects took ≥80% of their prescribed doses (P < 0.05). For patients who remained on treatment, the mean milligrams missed per day was significantly greater for RBV vs. RBP at 24 weeks. Conclusions First line treatment with RBP may offer the best prospect for less discontinuation and improved treatment adherence.

Original languageEnglish (US)
Pages (from-to)535-542
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume32
Issue number4
DOIs
StatePublished - Aug 1 2010

Fingerprint

Ribavirin
Hepatitis C
Hepacivirus
Registries
Therapeutics
Treatment Failure
Tablets

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Enhanced adherence to HCV therapy with higher dose ribavirin formulation : Final analyses from the ADHERE registry. / Alam, Imtiaz; Stainbrook, T.; Cecil, B.; Kistler, K. D.

In: Alimentary Pharmacology and Therapeutics, Vol. 32, No. 4, 01.08.2010, p. 535-542.

Research output: Contribution to journalArticle

@article{d78b2a2191c548f6844bb1a41dc614f6,
title = "Enhanced adherence to HCV therapy with higher dose ribavirin formulation: Final analyses from the ADHERE registry",
abstract = "Background Poor adherence to Hepatitis C virus (HCV) treatment is an important cause of treatment failure. Traditional ribavirin 200 mg (RBV) treatment is associated with a significant daily pill burden. RibaPak (RBP), available as 400 mg and 600 mg ribavirin tablets, offers simplified dosing at two pills daily. Aim To examine whether improved adherence was associated with RBP vs. RBV. Methods Accurate Dosing in Hepatitis C: Examining the RibaPak Experience (ADHERE) was a U.S., multi-centre, prospective registry capturing data on adherence with RBP vs. RBV in adults with HCV. Adherence was measured by the proportion of subjects remaining on treatment at weeks 4, 12 and 24; by pill counts; and by the proportion of subjects who took ≥80{\%} of their prescribed dose. Results A total of 503 patients (RBP = 346, RBV = 157) from 33 sites were included. A greater proportion of RBV vs. RBP subjects prematurely discontinued treatment. At 12 and 24 weeks, a greater proportion of RBP vs. RBV subjects took ≥80{\%} of their prescribed doses (P < 0.05). For patients who remained on treatment, the mean milligrams missed per day was significantly greater for RBV vs. RBP at 24 weeks. Conclusions First line treatment with RBP may offer the best prospect for less discontinuation and improved treatment adherence.",
author = "Imtiaz Alam and T. Stainbrook and B. Cecil and Kistler, {K. D.}",
year = "2010",
month = "8",
day = "1",
doi = "10.1111/j.1365-2036.2010.04381.x",
language = "English (US)",
volume = "32",
pages = "535--542",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Enhanced adherence to HCV therapy with higher dose ribavirin formulation

T2 - Final analyses from the ADHERE registry

AU - Alam, Imtiaz

AU - Stainbrook, T.

AU - Cecil, B.

AU - Kistler, K. D.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Background Poor adherence to Hepatitis C virus (HCV) treatment is an important cause of treatment failure. Traditional ribavirin 200 mg (RBV) treatment is associated with a significant daily pill burden. RibaPak (RBP), available as 400 mg and 600 mg ribavirin tablets, offers simplified dosing at two pills daily. Aim To examine whether improved adherence was associated with RBP vs. RBV. Methods Accurate Dosing in Hepatitis C: Examining the RibaPak Experience (ADHERE) was a U.S., multi-centre, prospective registry capturing data on adherence with RBP vs. RBV in adults with HCV. Adherence was measured by the proportion of subjects remaining on treatment at weeks 4, 12 and 24; by pill counts; and by the proportion of subjects who took ≥80% of their prescribed dose. Results A total of 503 patients (RBP = 346, RBV = 157) from 33 sites were included. A greater proportion of RBV vs. RBP subjects prematurely discontinued treatment. At 12 and 24 weeks, a greater proportion of RBP vs. RBV subjects took ≥80% of their prescribed doses (P < 0.05). For patients who remained on treatment, the mean milligrams missed per day was significantly greater for RBV vs. RBP at 24 weeks. Conclusions First line treatment with RBP may offer the best prospect for less discontinuation and improved treatment adherence.

AB - Background Poor adherence to Hepatitis C virus (HCV) treatment is an important cause of treatment failure. Traditional ribavirin 200 mg (RBV) treatment is associated with a significant daily pill burden. RibaPak (RBP), available as 400 mg and 600 mg ribavirin tablets, offers simplified dosing at two pills daily. Aim To examine whether improved adherence was associated with RBP vs. RBV. Methods Accurate Dosing in Hepatitis C: Examining the RibaPak Experience (ADHERE) was a U.S., multi-centre, prospective registry capturing data on adherence with RBP vs. RBV in adults with HCV. Adherence was measured by the proportion of subjects remaining on treatment at weeks 4, 12 and 24; by pill counts; and by the proportion of subjects who took ≥80% of their prescribed dose. Results A total of 503 patients (RBP = 346, RBV = 157) from 33 sites were included. A greater proportion of RBV vs. RBP subjects prematurely discontinued treatment. At 12 and 24 weeks, a greater proportion of RBP vs. RBV subjects took ≥80% of their prescribed doses (P < 0.05). For patients who remained on treatment, the mean milligrams missed per day was significantly greater for RBV vs. RBP at 24 weeks. Conclusions First line treatment with RBP may offer the best prospect for less discontinuation and improved treatment adherence.

UR - http://www.scopus.com/inward/record.url?scp=77954746102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954746102&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2010.04381.x

DO - 10.1111/j.1365-2036.2010.04381.x

M3 - Article

VL - 32

SP - 535

EP - 542

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 4

ER -